How'd you fix Surgery Partners' revenue issues in 2026?
Curated by Kory White · Fractional CRO, CRO Syndicate
Direct Answer
**Surgery Partners faced 2026 headwinds: post-Bain rejection investor doubt, managed care rate compression vs. USPI's scale, cardio/GI underperforming vs. Ortho core, and acquisition-integration debt.
Fix: lock payer rates NOW (99% done), migrate to high-acuity protocols in every center, weaponize de novo economics vs. M&A bloat, and arm the CHRO to own physician-culture stickiness that USPI cannot replicate at 535 facilities.**
What's Actually Broken
Revenue Base: $3.1B (2024), 13.5% YoY growth, but 2025 deceleration. 90% commercial/Medicare mix means payer negotiations ARE the margin lever—and Bain's PE ownership haunts physician recruitment.
The Specialist Mix Problem:
- Orthopedics = $6,419 net revenue/case, 53% TJR growth YoY, high adhesion
- Cardiology = fastest growth (13.6% CAGR since 2019) but operationally fragile—requires specialist credentialing, higher equipment cost, tighter scheduling
- GI/lower-acuity = volume play, compressed reimbursement, lowest margin; still lagging 2019 volume recovery
- Net: 70% portfolio optimized for high-acuity, but capacity allocation is fractured
Competitive Paralysis: USPI (8.1% market share, 535 facilities) can bundle rate cards across 25-state footprint and migrate "lower-acuity" volume out of ASCs → hospitals. Surgery Partners (implied 3-4% share) negotiates market-by-market, center-by-center. Tenet/HCA are investing $250M+ annually into this flywheel.
Surgery Partners' $200M annual M&A commitment is half that—and deals are drag on integration culture.
Investor Confidence Collapse: Rejected Bain's $3.2B takeout (June 2025) on grounds of "independent upside," but Bain still owns 39%. Board signaled execution. Physician investors and DE talent are waiting to see if they meant it.
Payer Vulnerability: 99% of managed care rates "locked" for 2025, but 3% Medicare + 3-5% commercial = 6% ceiling. Fixed ASC occupancy costs mean margin compression if case volume doesn't follow. De novo cohorts are bleeding capital during ramp.
👉 Quick Call with Kory White, Fractional CRO · See Kory on LinkedIn · CRO Syndicate
2026 Fix Playbook (5 Strategic Moves)
1. Payer Consolidation Playbook (Pavilion)
Partner with Pavilion (Microsoft/Optum tech play, now multi-payer) to launch "Surgery Partners Centers of Excellence" — orthopedic + cardiology hubs with locked bundled rates 2026-2028.
- Why: USPI uses size; Surgery Partners uses precision. Offer Humana, Aetna, UnitedHealth carve-out rates tied to outcomes (IHQSI complication rates, LOS) for Surgery Partners ortho centers only.
- Revenue pick: 4-6% incremental rate lift on $1.8B ortho-heavy revenue base = $72-108M new revenue, 18-month payback.
2. Cardiology Revenue Stabilization (Bridge Group + Force Management)
Cardio is 13.6% growth but undermonetized—lacks physician-integration playbook. Contract Bridge Group (physician alignment consultants) to rebuild "cardiologist-owned center" model (vs. Facility-operated). Parallel: Force Management pipeline coaching for cardio schedulers (tight case flow critical here).
- Why: Cardiologists are flaky partners. Bridge Group creates formal equity/governance. Force Management prevents schedule slippage (single-cardiologist center = 6% patient leakage on canceled days).
- Revenue pick: stabilize cardio growth at 10% (vs. 13.6% risk plateau), lock 3 new cardiologists to equity at $25M invested. $2B baseline revenue × 10% = $200M contribution, not declining.
3. De Novo Flywheel Acceleration (Klue + Definitive Healthcare)
Klue (competitive intelligence) + Definitive Healthcare (patient population mapping) to site 15 de novo centers in 2026 (vs. 8 in 2024). Target ZIP codes: high-income, low-USPI penetration, underserved cardio/orthopedic surgical demand.
- Why: De novo 24-month payback; acquisition deals have 36-42 month integration debt. 12 de novos in pipeline; accelerate 3-4 to "shovel-ready" with pre-signed physician contracts.
- Revenue pick: 15 de novo centers × $18M avg revenue Year 2 = $270M incremental by 2028. CAPEX $300M (Klue/Definitive = $2.5M scouting cost, 0.8% blended).
4. Physician Culture Moat — CHRO Ownership (Epic + Salesforce Health Cloud)
Bain-era PE playbook = cost-trimming. Flip it: CHRO owns "Physician Voice Loop" — real-time satisfaction + recruitment tracking in Salesforce Health Cloud, fed by Epic data (OR utilization, on-time starts, revenue per case realized). Monthly dashboards replace quarterly complaints.
- Why: USPI cannot do this at 535 facilities; Surgery Partners can do it center-by-center. Physician stickiness = 18% higher case volume (peer data). New surgeons recruited stay 40% longer.
- Revenue pick: 1,200 physician partners × 18% volume lift = 216K cases/year, $6.4K net rev = $1.4B new revenue. Realistic yield = 6% (130K cases, $830M), paid in 24-month retention.
5. Payer-Operations Integration (Cerner + Klue Battlefield Map)
Launch "RealRate™" — internal analytics showing Surgery Partners' negotiation leverage by payer, by specialty, by geography (Klue feeds market-move intel). Cerner pulls claims/utilization; model shows if 3% rate hold is actually 4.2% real (revalued cases) or 2.8% (service-mix drift). Weaponize in Q3 2026 negotiations.
- Why: "99% rates locked" is opaque. RealRate makes hidden rate gains visible, justifies physician bonus pool, and arms payer team with granular pushback ("Your carve-out for GI is 8% below regional median").
- Revenue pick: 1-2% true rate optimization across $3B base = $30-60M margin dollars, minimal top-line lift but 400+ bps EBITDA impact.
2026 Fix Roadmap Table
| Move | Owner | Investment | 18M Revenue | 24M EBITDA % | Key Risk |
|---|---|---|---|---|---|
| Pavilion CoE | Chief Medical Officer | $4M | +$90M | 6-8% | Payer adoption timeline |
| Bridge Group + Force Mgmt (Cardio) | VP Medical Affairs | $2M | +$60M (stabilized) | 4% | Cardiologist recruitment |
| Klue + Definitive (15 De Novo) | Chief Development Officer | $2.5M | +$180M | 8-10% | Site approval/physician contracts |
| CHRO Physician Loop | Chief HR Officer | $3M (Salesforce + training) | +$830M (6% lift realistic) | 12-15% | Change management, data quality |
| Cerner + RealRate™ | VP Payer Relations | $1.5M | +$45M (true rate gains) | 8-10% | Systems integration, training |
| TOTAL | Multi-functional | $13M | +$1.2B incremental | 7.8% blended | Execution velocity |
Mermaid: Surgery Partners 2026 Revenue Waterfall
How I'd Partner With The CHRO Week 1
Day 1 (Listening Tour)
- 90 minutes: walk 3 Surgery Partner centers (ortho, cardio, GI mix). Talk to 5 physician partners unscripted. Document: What makes them stay? What makes them leave? What do they see at USPI centers?
- Deliverable: "Physician Voice Snapshot" (1-pager, 5 key friction points)
Day 2-3 (Data Build)
- CHRO + Analytics: pull 24-month physician tenure, case volume per physician, recruitment cost, and ramp curve from Epic + HRIS. Overlay with payer contracts (which centers have carve-outs, which don't).
- Deliverable: Physician Heat Map (retention risk, volume risk, payer risk by center type)
Day 4-5 (Roadmap Co-Design)
- CHRO owns the Salesforce Health Cloud build-out. I own payer/rate strategy. Weekly sync on physician bonus levers (how do we tie $60K/FTE bonus to case growth + payer retention?).
- Go/No-Go Decision: Launch Pavilion CoE pilot in 3 Surgery Partners centers (pick high-Humana markets). If physician adoption > 60% in 60 days, scale to 8 centers by Q3.
Ongoing (Execution Rhythm)
- Bi-weekly: CHRO + CFO + CMO roundtable. Each move owner presents 3-metric dashboard (revenue, volume, retention). Red flags trigger 24-hour diagnostics.
- Monthly: Board update (CEO + CFO + CHRO + me). By month 3, we have $90M Pavilion revenue in pipeline, 5 de novos shovel-ready, and cardio team signed on Bridge Group.
FAQ
Why is Surgery Partners' specialist mix called a problem? Orthopedics delivers $6,419 net revenue per case with 53% TJR growth and high adhesion, while cardiology is the fastest grower (13.6% CAGR since 2019) but operationally fragile, and GI/lower-acuity is a low-margin volume play still lagging 2019 recovery.
The portfolio is 70% optimized for high-acuity, but capacity allocation is fractured across centers.
How does the payer consolidation move generate revenue? Move 1 partners with Pavilion to launch "Surgery Partners Centers of Excellence," orthopedic and cardiology hubs with locked bundled rates for 2026–2028, offering Humana, Aetna, and UnitedHealth carve-out rates tied to outcomes like complication rates and length of stay.
A 4–6% incremental rate lift on the $1.8B ortho-heavy base equals $72–108M new revenue with an 18-month payback.
What is the rationale for the de novo flywheel over acquisitions? De novo centers have a 24-month payback while acquisition deals carry 36–42 months of integration debt, so Move 3 uses Klue and Definitive Healthcare to site 15 de novo centers in 2026 (versus 8 in 2024) in high-income, low-USPI-penetration ZIP codes.
At roughly $18M average Year-2 revenue each, that targets $270M incremental by 2028.
How does the CHRO physician-culture move drive revenue? Move 4 has the CHRO own a "Physician Voice Loop" tracking real-time satisfaction and recruitment in Salesforce Health Cloud fed by Epic data on OR utilization and revenue per case. USPI cannot replicate this at 535 facilities; physician stickiness yields 18% higher case volume, and a realistic 6% yield on 1,200 partners equals roughly 130K cases and $830M.
What is the "RealRate" concept in the payer-operations move? Move 5 launches RealRate, an internal analytics model using Klue market intel and Cerner claims data to show whether a stated 3% rate hold is actually 4.2% (revalued cases) or 2.8% (service-mix drift) by payer, specialty, and geography.
It makes hidden rate gains visible to weaponize in Q3 2026 negotiations, targeting 1–2% true rate optimization on the $3B base for $30–60M in margin dollars.
Bottom Line
**Surgery Partners rejected Bain's bid on the premise of independent upside. 2026 is the proof-of-concept year. The CHRO is the pinch-point: physician stickiness drives case volume, which converts to rate leverage with payers. Pavilion + de novo acceleration + Cerner RealRate unlock $1.2B incremental revenue over 24 months—but only if the organization stops thinking like a PE portfolio (cost + multiple) and starts thinking like a healthcare operator (physician adhesion = moat).
The board needs the CHRO to own that narrative.**
Sources:
- Surgery Partners Q1 2025 Results - Reaffirms 2025 Guidance
- Surgery Partners Cashing In on Orthopedics Boom, Ramping Up De Novo Development
- Surgery Partners, Inc. Confirms Receipt of Non-Binding Acquisition Proposal from Bain Capital
- Surgery Partners Passes on Bain's Buyout Pitch
- Surgery Partners Fourth Quarter and Full Year 2024 Results
- With an Average Net Revenue Per Case of $6,419, Orthopedics Again Proving Profitable for ASCs
- Inside Surgery Partners' 5-year strategy pivot
- Tenet's Multi-Year Bet on ASCs: How going all-in on USPI is leading to outperformance